Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Expert Rev Hematol. 2012 Aug;5(4):409-25. doi: 10.1586/ehm.12.28.
Allogeneic hematopoietic stem cell transplantation (HCT) is currently the standard of care for most patients with high-risk acute leukemias and some other hematologic malignancies. Although HCT can be curative, many patients who undergo allogeneic HCT will later relapse. There is, therefore, a critical need for the development of novel post-HCT therapies for patients who are at high risk for disease recurrence following HCT. One potentially efficacious approach is adoptive T-cell immunotherapy, which is currently undergoing a renaissance that has been inspired by scientific insight into the key issues that impeded its previous clinical application. Translation of the next generation of adoptive T-cell therapies to the allogeneic HCT setting, using donor T cells of defined specificity and function, presents a unique set of challenges and opportunities. The challenges, progress and future of adoptive T-cell therapy following allogeneic HCT are discussed in this review.
异基因造血干细胞移植（HCT）目前是大多数高危急性白血病和一些其他血液恶性肿瘤患者的标准治疗方法。尽管 HCT 可能具有治愈性，但许多接受异基因 HCT 的患者后来会复发。因此，对于 HCT 后疾病复发风险高的患者，迫切需要开发新的移植后治疗方法。一种潜在有效的方法是过继性 T 细胞免疫疗法，该疗法目前正在复兴，这得益于对阻碍其以前临床应用的关键问题的科学深入了解。使用具有明确特异性和功能的供体 T 细胞，将下一代过继性 T 细胞疗法应用于异基因 HCT 环境，提出了一系列独特的挑战和机遇。本文综述了异基因 HCT 后过继性 T 细胞治疗的挑战、进展和未来。
